Biocon Upbeat As It Tries To Undercut Roche On Herceptin
This article was originally published in PharmAsia News
Executive Summary
India’s Biocon has high expectations for its Herceptin biosimilar, but patient groups are vocal in their criticism of the drug’s price in comparison to Roche’s.